From Yahoo Finance: 2025-06-11 20:23:00

Cytokinetics, Incorporated is listed as one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan maintains an Overweight rating on CYTK but reduces price target to $53 from $71. Aficamten’s revised revenue projections prompt this change, reflecting slower launch pace for obstructive hypertrophic cardiomyopathy (oHCM) expected to impact adoption rates.

Despite slower launch trajectory, Cytokinetics’ experimental treatment for oHCM, Aficamten, remains promising with unique pharmacology, safety, and dosing flexibility. JPMorgan still views the drug positively, noting the lower price target is based on modified commercial ramp assumptions, not a shift in opinion on the drug’s efficacy or strategic value.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company specializing in muscle activators and inhibitors as potential treatments for fatal diseases affecting muscle function. While CYTK shows investment potential, some AI stocks may offer higher upside potential and lower downside risk, especially in light of current economic trends.

There are no disclosures provided in the news article.



Read more at Yahoo Finance: Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan